Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly

摘要

h3 class="Heading"Background and Objectives/h3p id="Par1" class="Para"Management of hypertension and dyslipidemia is important when considering cardiovascular disease risk; however, achievement of optimal lipid and blood pressure (BP) targets in clinical practice remains inadequate. This analysis sought to estimate the frequency, effectiveness, and safety of co-administrated atorvastatin and perindopril in routine care. h3 class="Heading"Methods/h3p id="Par2" class="Para"We conducted a post hoc analysis of four Canadian, prospective, multi-center, observational studies assessing real-life effectiveness and safety of perindopril?+?atorvastatin in mild-to-moderate hypertensive patients with concomitant dyslipidemia over 16?weeks. The safety population comprised patients receiving one or more doses of free combination perindopril?+?atorvastatin; the full analysis set (FAS) received perindopril?+?atorvastatin at baseline, with one or more post-baseline systolic BP measurements while on treatment. h3 class="Heading"Results/h3p id="Par3" class="Para"A total of 3541 and 3172 patients were included in the safety population and FAS, respectively. At the last observation carried forward, significant reductions in mean systolic BP (? 18.0?mmHg; p ?0.001) and diastolic BP (? 8.9?mmHg; p ?0.001) were observed; target BP was achieved by 73.1% of patients. Emergent adverse events (AEs) were reported in 8.0% of patients, the most common being cough (4.5% of patients), headache (0.9%), and dizziness (0.8%). Four serious AEs were reported among three (0.1%) patients. No differences were observed in effectiveness or safety between studies. h3 class="Heading"Conclusions/h3p id="Par4" class="Para"Concomitant perindopril?+?atorvastatin therapy demonstrated similar efficacy across all studies, with significant reductions in BP and achievement of target BP levels observed in a real-world setting. Results align with known safety profiles of atorvastatin and perindopril, with no unexpected AEs observed when compared with data from treatment with the individual drugs.